Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof
Industry Webcast Sponsored by Novartis; Not for CME/CE Credit
Click here to view full Prescribing Information
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content.